Celularity warns of going concern as revenues plunge, losses widen; asset sales, financings underway

Celularity Inc. (NASDAQ: GXGX) - quick inside view

Snapshot
Celularity is a clinical‑stage regenerative medicine and biomaterials company that posted sharply lower revenues in H1 2025, continued large operating losses, a stretched balance sheet (liabilities > assets) and formal going‑concern disclosures. Management is cutting some costs, pursuing financings and has executed several post‑period financing and asset‑sale actions to shore up liquidity.

Key facts & statistics (from Form 10‑Q, amounts in thousands)

* Cash and cash equivalents: $863; Restricted cash: $10,073; Cash + restricted cash (per cash flow): $10,936

* Total assets: $120,283

* Total liabilities: $145,780; Stockholders' (deficit) equity: $(25,497)

* Accounts receivable, net: $11,152

* Inventory, net: $11,819 (current portion $4,410; noncurrent $7,409)

* Total debt: $43,437 (short‑term unaffiliated $2,648; related‑party short & long: $4,297 short, $36,492 long)

* Warrant liabilities (fair value): $8,780 (note: fair‑value changes hit P&L)

* Accumulated deficit: $944,025

* Shares outstanding (June 30, 2025): 24,610,151; As of Aug 29, 2025: 26,691,477

Income statement - headline results

* Total net revenues - Q2 2025: $5,736 vs Q2 2024: $12,111 (down 52.6% YoY); Six months 2025: $17,162 vs 2024: $26,792 (down 35.9%)

* Product sales - Q2 2025: $2,379 vs Q2 2024: $9,963 (down 76.1%); Six months 2025: $11,397 vs 22,806 (down 50.0%)

* License, royalty & other - Q2 2025: $2,082 vs Q2 2024: $870 (up 139.3%)

* Loss from operations - Q2 2025: $(15,864) vs Q2 2024: $(10,175)

* Net loss - Q2 2025: $(24,524) vs Q2 2024: $(6,488); Six months 2025: $(44,278) vs $(28,501)

* Net loss per share - Six months 2025: $(1.86); weighted average shares: 23,775,535

Positive items inside the numbers

* Licensing/royalty revenue grew materially in Q2 2025 (Q2: $2,082 vs $870), showing diversification beyond direct product sales.

* Services (biobanking/processing) were stable: Q2 2025 $1,275 ≈ Q2 2024 $1,278.

* Management reduced spending in key categories: R&D down (Q2: −11.8% YoY; six months: −26.6% YoY) and SG&A down (Q2: −20.6% YoY; six months: −10.2% YoY), reflecting cost containment.

* Recent financings and agreements post‑period: June 23, 2025 PIPE (739,286 shares at $1.40; proceeds ~ $1.035M recorded as $1,010 liability to be issued), July 14, 2025 private placement (~$2.0M gross), and an August 13, 2025 Asset Purchase Agreement (IP sale to Celeniv for $33,812) intended to pay down large related‑party loans.

Negative items and risks (income statement & beyond)

* Product sales collapsed (Q2 down 76% YoY; six months down 50%), driving most of the revenue decline.

* Cost of revenues increased despite revenue decline - includes significant one‑time items: Q2 included $1.8M write‑off of capitalized bulk material costs and $1.2M Rebound milestone accrual; six months included $2.5M write‑off and $1.5M milestone - pressuring gross margins.

* Large non‑operating charges: H1 other expense $(17,928) driven by higher interest expense, loss on debt extinguishment ($5,736), and unfavorable fair‑value movements on warrants and debt - these make losses deeper than operating loss alone.

* Balance sheet stressed: liabilities $145.8M > assets $120.3M → stockholders' deficit $(25.5M). Going‑concern language: management states "substantial doubt" and need to raise capital to fund operations.

* High customer concentration: two customers ≈ 45% of revenue for six months ended June 30, 2025; accounts receivable concentration risk noted.

* Complex debt and warrant structure (many forbearances and related‑party loans) increases refinancing and dilution risk.

* Nasdaq delisting risk: Notice received for late filings; Nasdaq granted exception but company must file by Aug 31, 2025 to retain listing - failure could materially harm liquidity and access to capital.

Operational and liquidity highlights

* Net cash used in operating activities H1 2025: $(3,992) vs $(7,851) prior year - improvement driven by working‑capital movements.

* Cash + restricted cash at 6/30/25: $10,936 - but unrestricted cash only $863; substantial portion is restricted (letter of credit tied to lease).

* Total debt as of 6/30/25: $43,437; many loans subject to forbearance and amendment; related‑party debt (RWI, C.V. Starr, CEO note) is the majority.

* Post‑period transactions intended to address debt: July 21, 2025 promissory note $6,812 (assigned to Celeniv); Aug 13, 2025 APA with Celeniv (IP sale $33,812) to repay RWI Bridge Loan ($27,000) and the July 21 note.

Bottom line - what's happening inside

Celularity is executing cost reductions and pursuing financing/asset sales to cover a cash shortfall while trying to stabilize revenues via licensing and services. However, product revenue has fallen sharply, one‑time cost write‑downs and milestone accruals hit gross margins, and non‑operating finance charges (warrant and debt fair‑value changes, interest, extinguishment losses) drive heavy net losses. The balance sheet shows a deficit and multiple creditor forbearance arrangements. The company's near‑term survival depends on successful closings of recent financings/asset sales, meeting Nasdaq filing requirements, and either restoring product sales or securing additional capital. Investors should treat the situation as high risk: potential for further dilution, restructuring or strategic alternatives if funding and Nasdaq compliance are not secured.

If you want, I can pull a concise timeline of the post‑period financings and the exact cash flow treatment or prepare a short investor checklist of triggers to watch (Nasdaq filing, IP sale close, debt paydown amounts, cash runway).